EMB-01 (bafisontamab) is a bispecific EGFR/cMET-targeted antibody currently under evaluation in a first-in-human (FIH) phase I/II study in advanced neoplasms, including NSCLC [104]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.